Clinical Pathology Evaluation in Pet Rabbits Vaccinated Against Rabbit Hemorrhagic Disease Virus 2 (RHDV2)
- PMID: 39457958
- PMCID: PMC11504023
- DOI: 10.3390/ani14203029
Clinical Pathology Evaluation in Pet Rabbits Vaccinated Against Rabbit Hemorrhagic Disease Virus 2 (RHDV2)
Abstract
A recombinant vaccine for rabbit hemorrhagic disease virus 2, a highly pathogenic virus, was granted emergency use authorization in the United States after the detection and spread of the virus starting in 2018. The goal of the current study was to assess pet rabbits (n = 29) through physical examination and routine clinical pathology testing using repeated assessments post-vaccination. In addition, seroconversion was also monitored after the initial vaccination and booster vaccination. Neither owners nor clinicians detected any physical abnormalities in relationship to the vaccine protocol. Hematological and clinical biochemistry testing showed some changes although median values were within species specific reference intervals. A significant increase in antibody levels was observed at day 21 (post-initial vaccination) and day 49 (post-booster vaccination) versus that present at baseline (p < 0.0001). However, variability in study rabbits was noted with some individuals showing low antibody levels as well as a lower overall response in older rabbits (r = -0.56, p = 0.006). A second cohort of rabbits was assessed at 11-12 months post-initial vaccination. In this second group, antibody levels were not significantly different from baseline levels (p = 0.21). Additional studies should be conducted to further define the variability in seroconversion and the term of protection in pet rabbits as the industry moves forward in the optimization of RHDV2 vaccines.
Keywords: ELISA; RHDV2; antibody; biochemistry; hematology; lagomorph.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Vaccination against Rabbit Hemorrhagic Disease Virus 2 (RHDV2) Using a Baculovirus Recombinant Vaccine Provides Durable Immunity in Rabbits.Viruses. 2024 Mar 30;16(4):538. doi: 10.3390/v16040538. Viruses. 2024. PMID: 38675881 Free PMC article.
-
Evaluation of comparative effect between aluminum hydroxide gel and montanide (ISA 70) in potency and protection of locally prepared rabbit hemorrhagic disease virus 2 (RHDV2) vaccines in rabbits.BMC Vet Res. 2024 Sep 11;20(1):407. doi: 10.1186/s12917-024-04239-w. BMC Vet Res. 2024. PMID: 39261948 Free PMC article.
-
Challenges in the rabbit haemorrhagic disease 2 (RHDV2) molecular diagnosis of vaccinated rabbits.Vet Microbiol. 2017 Jan;198:43-50. doi: 10.1016/j.vetmic.2016.12.006. Epub 2016 Dec 5. Vet Microbiol. 2017. PMID: 28062006
-
A novel vaccine candidate against rabbit hemorrhagic disease virus 2 (RHDV2) confers protection in domestic rabbits.Am J Vet Res. 2022 Nov 7;83(12):ajvr.22.05.0095. doi: 10.2460/ajvr.22.05.0095. Am J Vet Res. 2022. PMID: 36327167
-
Characterization of protective humoral and cellular immune responses against RHDV2 induced by a new vaccine based on recombinant baculovirus.Vaccine. 2019 Jul 9;37(30):4195-4203. doi: 10.1016/j.vaccine.2019.04.061. Epub 2019 Jun 8. Vaccine. 2019. PMID: 31182325
References
-
- Liu S., Xue H., Pu B., Qian N. A new viral disease in rabbits. Anim. Husb. Vet. Med. (Xumu Yu Shouyi) 1984;16:253–255.
-
- Root J.J., Gidlewski T. Rabbit Hemorrhagic Disease. In: Jessup D.A., Radcliffe R.W., editors. Wildlife Disease and Health in Conservation. John Hopkins University Press; Baltimore, MD, USA: 2023. pp. 259–272.
LinkOut - more resources
Full Text Sources